{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:25:40Z","timestamp":1783023940437,"version":"3.54.6"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clbc.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:24:03Z","timestamp":1776234243000},"page":"113-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Palbociclib in Patients With HR+\/HER2\u2212 Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review"],"prefix":"10.1016","volume":"26","author":[{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Louise","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Jean","family":"Watters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Korytowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Pasupuleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.04.010_bib0001","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-6-179","article-title":"Clinical management of women with metastatic breast cancer: a descriptive study according to age group","volume":"6","author":"Manders","year":"2006","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.010_bib0003","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10549-015-3352-0","article-title":"Retrospective analysis of metastatic behaviour of breast cancer subtypes","volume":"150","author":"Savci-Heijink","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.04.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920987657","article-title":"Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program","volume":"13","author":"Bertho","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"19","key":"10.1016\/j.clbc.2026.04.010_bib0005","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.7150\/jca.26825","article-title":"Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis","volume":"9","author":"Kono","year":"2018","journal-title":"J Cancer"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.010_bib0006","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1200\/JCO.2017.74.6917","article-title":"US Food and Drug Administration pooled analysis to assess the impact of bone-only metastatic breast cancer on clinical trial outcomes and radiographic assessments","volume":"36","author":"Wedam","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20 Pt 2","key":"10.1016\/j.clbc.2026.04.010_bib0007","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.04.010_bib0008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41523-018-0054-x","article-title":"Characterization of bone only metastasis patients with respect to tumor subtypes","volume":"4","author":"Parkes","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2026.04.010_bib0009","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7150\/jca.1.80","article-title":"Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST","volume":"1","author":"Costelloe","year":"2010","journal-title":"J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.010_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2026.04.010_bib0011","unstructured":"National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes, https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html; 2025 [accessed 10 April 2025]."},{"issue":"35","key":"10.1016\/j.clbc.2026.04.010_bib0012","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.04.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101541","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"8","author":"Im","year":"2023","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.010_bib0015","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.04.010_bib0016","unstructured":"U.S. Food and Drug Administration. Ibrance (palbociclib) \u2013 prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/207103s021,212436s009lbl.pdf; 2025 [accessed 21 April 2025]."},{"key":"10.1016\/j.clbc.2026.04.010_bib0017","unstructured":"European Medicines Agency. Ibrance (palbociclib) \u2013 summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ibrance-epar-product-information_en.pdf; 2025 [accessed 06 October 2025]."},{"issue":"4","key":"10.1016\/j.clbc.2026.04.010_bib0018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.010_bib0019","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.010_bib0020","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/curroncol30020143","article-title":"Harnessing real-world evidence to advance cancer research","volume":"30","author":"Tang","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2026.04.010_bib0021","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.breast.2021.12.015","article-title":"The emerging role of real-world data in advanced breast cancer therapy: recommendations for collaborative decision-making","volume":"61","author":"Cottu","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.04.010_bib0022","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.010_bib0024","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000051263","article-title":"Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer\u2019s disease drug trials","volume":"12","author":"Oremus","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.clbc.2026.04.010_bib0025","unstructured":"Wells G.A., Shea B., O\u2019Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp; 2021 [accessed 09 April 2025]."},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0026","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.clbc.2026.04.010_bib0027","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.04.010_bib0028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.08.011","article-title":"Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3","volume":"104","author":"Cristofanilli","year":"2018","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.010_bib0029","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.31557\/APJCP.2024.25.9.3039","article-title":"Comparing ribociclib versus palbociclib as a second line treatment in combination with fulvestrant in metastatic breast cancer: a randomized clinical trial","volume":"25","author":"Ahmed Shaaban","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.clbc.2026.04.010_bib0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11523-021-00826-1","article-title":"Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice","volume":"16","author":"Brufsky","year":"2021","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0031","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice","volume":"23","author":"DeMichele","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.010_bib0032","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2217\/fon-2023-0858","article-title":"Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer","volume":"20","author":"Robert","year":"2024","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0033","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","article-title":"Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2026.04.010_bib0034","article-title":"CDK4\/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: a real-world and propensity score-adjusted comparison","volume":"40","author":"Coutinho-Almeida","year":"2024","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0035","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1186\/s12885-024-12765-x","article-title":"Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR\u2009+\u2009\/HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand","volume":"24","author":"Dajsakdipon","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0036","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/mco.2022.2552","article-title":"Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: an experience at two cancer centers in Saudi Arabia","volume":"17","author":"Al-Foheidi","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0037","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13058-023-01678-5","article-title":"Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice","volume":"25","author":"Alves da Costa","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.010_bib0038","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10549-024-07312-y","article-title":"Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer","volume":"206","author":"Baltussen","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.04.010_bib0039","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2021.08.610","article-title":"327P predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole","volume":"32","author":"Behrouzi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.04.010_bib0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.breast.2021.10.010","article-title":"Palbociclib in combination with aromatase inhibitors in patients \u2265 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: a real-world multicentre UK study","volume":"60","author":"El Badri","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.04.010_bib0041","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/8994954","article-title":"Hormonal-receptors-positive and HER2-negative patients with metastatic breast cancer treated with first-line palbociclib and hormonal therapy: impact of first-cycle neutropenia and dose reduction on therapeutic outcome","volume":"2023","author":"Elnaghi","year":"2023","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2026.04.010_bib0042","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2147\/PPA.S401480","article-title":"Palbociclib adherence and persistence in patients with hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2-) metastatic breast cancer","volume":"17","author":"Engel-Nitz","year":"2023","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.010_bib0043","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/0284186X.2023.2194030","article-title":"A retrospective, non-interventional study of breast cancer patients diagnosed with ER+\/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark","volume":"62","author":"Garly","year":"2023","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0044","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-018-4827-6","article-title":"Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer","volume":"171","author":"Hoste","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13058-022-01601-4","article-title":"On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2\/3 study with immune correlates","volume":"25","author":"Kim","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2026.04.010_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.759150","article-title":"Which clinicopathologic parameters suggest primary resistance to palbociclib in combination with letrozole as the first-line treatment for hormone receptor-positive, HER2-negative advanced breast cancer?","volume":"11","author":"Kim","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.010_bib0047","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.4143\/crt.2022.1543","article-title":"Efficacy of limited dose modifications for palbociclib-related grade 3 neutropenia in hormone receptor-positive metastatic breast cancer","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.010_bib0048","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/curroncol29020089","article-title":"Real-world treatment patterns and clinical effectiveness of palbociclib plus an aromatase inhibitor as first-line therapy in advanced\/metastatic breast cancer: analysis from the US Syapse Learning Health Network","volume":"29","author":"Law","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.010_bib0049","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4143\/crt.2020.451","article-title":"Real-world clinical data of palbociclib in Asian metastatic breast cancer patients: experiences from eight institutions","volume":"53","author":"Lee","year":"2021","journal-title":"Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.010_bib0050","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3390\/cancers15102810","article-title":"Risk factors for palbociclib-induced early developing neutropenia in patients with hormone receptor-positive metastatic breast cancer","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"44","key":"10.1016\/j.clbc.2026.04.010_bib0051","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027710","article-title":"Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+\/HER2- patients with metastatic breast cancer","volume":"100","author":"Li","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.010_bib0052","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2217\/fon-2020-0744","article-title":"Treatment patterns and clinical outcomes of palbociclib-based therapy received in US community oncology practices","volume":"17","author":"Lin","year":"2021","journal-title":"Future Oncol"},{"issue":"9 suppl","key":"10.1016\/j.clbc.2026.04.010_bib0053","article-title":"Abstract PO5-05-05: clinical outcomes of CDK4\/6 inhibitors in patients with bone only metastatic breast cancer","volume":"84","author":"Mardani","year":"2024","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.clbc.2026.04.010_bib0054","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1097\/CM9.0000000000002240","article-title":"Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population","volume":"135","author":"Mo","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.010_bib0055","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.21873\/anticanres.16447","article-title":"Optimal treatment of hormone receptor-positive advanced breast cancer patients with palbociclib","volume":"43","author":"Morita","year":"2023","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.010_bib0056","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.clinthera.2022.11.004","article-title":"Real-world treatment patterns and clinical outcomes associated with palbociclib combination therapy: a multinational, pooled analysis from the Ibrance Real World Insights study","volume":"44","author":"Mycock","year":"2022","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.010_bib0057","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/medicina59030557","article-title":"Does proton pump inhibitors decrease the efficacy of palbociclib and ribociclib in patients with metastatic breast cancer?","volume":"59","author":"Odabas","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.clbc.2026.04.010_bib0058","doi-asserted-by":"crossref","DOI":"10.1177\/1178223420983843","article-title":"Real-world outcomes of treating advanced breast cancer patients with palbociclib: a multicenter retrospective cohort study in Japan-the KBCOG-14 study","volume":"14","author":"Odan","year":"2020","journal-title":"Breast Cancer (Auckl)"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.010_bib0059","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1002\/jcp.27832","article-title":"Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience","volume":"234","author":"Pizzuti","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.clbc.2026.04.010_bib0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.breast.2020.11.008","article-title":"Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer","volume":"54","author":"Porte","year":"2020","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.010_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253722","article-title":"Efficacy and safety of palbociclib and ribociclib in patients with estrogen and\/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice","volume":"16","author":"Rath","year":"2021","journal-title":"PLoS One"},{"issue":"15 suppl","key":"10.1016\/j.clbc.2026.04.010_bib0062","article-title":"Palbociclib in hormone positive metastatic breast cancer: a real world multicenter Indian experience","volume":"38","author":"Rauthan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.010_bib0063","first-page":"329","article-title":"Observational real world data with palbociclib associated to hormone therapy for advanced breast carcinoma","volume":"45","author":"Sampedro-Gimeno","year":"2021","journal-title":"Farm Hosp"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.010_bib0064","first-page":"168","article-title":"Clinical benefit and safety of palbociclib in hormone positive breast cancer with visceral metastasis: real-world experience from a tertiary cancer center","volume":"46","author":"Sandeep","year":"2024","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.010_bib0065","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.clbc.2023.05.009","article-title":"Effect of concurrent proton pump inhibitors with palbociclib tablets for metastatic breast cancer","volume":"23","author":"Schieber","year":"2023","journal-title":"Clin Breast Cancer"},{"issue":"19","key":"10.1016\/j.clbc.2026.04.010_bib0066","first-page":"6138","article-title":"Clinical efficacy of palbociclib-based therapy in women with HR+\/HER2- metastatic breast cancer in the real-world setting for Chinese women: a comparison with the IRIS study","volume":"25","author":"Shangguan","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"21","key":"10.1016\/j.clbc.2026.04.010_bib0067","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1002\/cam4.4295","article-title":"Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia","volume":"10","author":"Sun","year":"2021","journal-title":"Cancer Med"},{"issue":"5 suppl","key":"10.1016\/j.clbc.2026.04.010_bib0068","doi-asserted-by":"crossref","first-page":"v114","DOI":"10.1093\/annonc\/mdz242.022","article-title":"Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: real-world progression-free survival analysis","volume":"30","author":"Torres","year":"2019","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.clbc.2026.04.010_bib0069","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.3390\/cancers15174360","article-title":"Effectiveness and safety of palbociclib plus endocrine therapy in patients with advanced breast cancer: a multi-center study in China","volume":"15","author":"Wu","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12885-023-10568-0","article-title":"Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.010_bib0071","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12282-024-01575-5","volume":"31","author":"Yoshinami","year":"2024","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0072","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1097\/CAD.0000000000001210","article-title":"The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis","volume":"33","author":"Zhang","year":"2022","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clbc.2026.04.010_bib0073","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221132926","article-title":"Early application of palbociclib plus endocrine therapy in HR+\/HER2- metastatic breast cancer: a better choice based on data from the Chinese population","volume":"21","author":"Zhang","year":"2022","journal-title":"Technol Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.clbc.2026.04.010_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101604","article-title":"PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: a prospective real-world TOG study","volume":"14","author":"Avc\u0131","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.010_bib0075","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-017-4623-8","article-title":"Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer","volume":"168","author":"du Rusquec","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.010_bib0076","doi-asserted-by":"crossref","first-page":"oyae291","DOI":"10.1093\/oncolo\/oyae291","article-title":"Real-world effectiveness of palbociclib plus endocrine therapy in HR+\/HER2- advanced breast cancer: final results from the POLARIS trial","volume":"30","author":"Tripathy","year":"2025","journal-title":"Oncologist"},{"issue":"22","key":"10.1016\/j.clbc.2026.04.010_bib0077","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1002\/cam4.4767","article-title":"Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: a multicenter ambispective real-world study","volume":"11","author":"Shen","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0078","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","article-title":"Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.010_bib0079","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","article-title":"Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2- advanced breast cancer (PALOMA-1, TRIO-18)","volume":"183","author":"Finn","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.010_bib0080","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.04.010_bib0081","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.breast.2022.11.005","article-title":"Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor\u2012positive\/human epidermal growth factor receptor 2\u2012negative advanced breast cancer: post hoc analyses from PALOMA-2 and PALOMA-3","volume":"66","author":"Rugo","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0082","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13058-020-01263-0","article-title":"Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies","volume":"22","author":"Ettl","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"3 suppl","key":"10.1016\/j.clbc.2026.04.010_bib0083","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0959-8049(18)30581-1","article-title":"Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in first-line postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2 bone metastases subgroup","volume":"92","author":"Ettl","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.010_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.010_bib0085","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study","volume":"36","author":"Provenzano","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.04.010_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105570","article-title":"Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR-positive\/HER2-negative metastatic breast cancer in United States routine clinical practice","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:01:38Z","timestamp":1783022498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1526820926000625"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.010","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palbociclib in Patients With HR+\/HER2\u2212 Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}